UY35834A - Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon - Google Patents

Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon

Info

Publication number
UY35834A
UY35834A UY0001035834A UY35834A UY35834A UY 35834 A UY35834 A UY 35834A UY 0001035834 A UY0001035834 A UY 0001035834A UY 35834 A UY35834 A UY 35834A UY 35834 A UY35834 A UY 35834A
Authority
UY
Uruguay
Prior art keywords
piperazinas
caseína
quinasa
pirazolo
epsilon
Prior art date
Application number
UY0001035834A
Other languages
English (en)
Spanish (es)
Inventor
Velaparthi Upender
Chetan Padmakar Darne
Liu Peiying
Mark D Wittman
Bradley C Pearce
Araujo Erika
Dasgupta Bireshwar
Jalathi Surendran Nair
Sakthi Kumaran Janakiraman
Chandrasekhar Reddy Rachamreddy
Mettu Mallikarjuna Rao
Arul Mozhi Selvan Subbiah Karuppiah
Bandreddy Subba Reddy
Nagalakshmi Pulicharla
Rajesh Onkardas Bora
Shilpa Holehatti Maheshwarappa
Selvakumar Kumaravel
Mullick Dibakar
Sistla Ramesh
Original Assignee
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Company Una Corporación Del Estado De Delaware filed Critical Bristol Myers Squibb Company Una Corporación Del Estado De Delaware
Publication of UY35834A publication Critical patent/UY35834A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
UY0001035834A 2013-11-14 2014-11-13 Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon UY35834A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361904116P 2013-11-14 2013-11-14

Publications (1)

Publication Number Publication Date
UY35834A true UY35834A (es) 2015-05-29

Family

ID=51952052

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001035834A UY35834A (es) 2013-11-14 2014-11-13 Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon

Country Status (9)

Country Link
US (3) US9598423B2 (enExample)
EP (2) EP3068784B1 (enExample)
JP (2) JP6494624B2 (enExample)
CN (2) CN105916855B (enExample)
AR (1) AR098414A1 (enExample)
ES (2) ES2718218T3 (enExample)
TW (1) TW201605859A (enExample)
UY (1) UY35834A (enExample)
WO (2) WO2015073767A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR098414A1 (es) 2013-11-14 2016-05-26 Bristol Myers Squibb Co PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e
EP3112369A4 (en) * 2014-02-27 2017-09-20 The University of Tokyo Fused pyrazole derivative having autotaxin inhibitory activity
MA41338B1 (fr) * 2015-01-16 2019-07-31 Hoffmann La Roche Composés de pyrazine pour le traitement de maladies infectieuses
CA3017020C (en) 2016-03-07 2024-01-16 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
WO2017156071A1 (en) 2016-03-09 2017-09-14 Blade Therapeutics, Inc. Cyclic keto-amide compounds as calpain modulators and methods of production and use thereof
CN109153682B (zh) * 2016-05-20 2021-05-25 豪夫迈·罗氏有限公司 用于治疗感染性疾病的具有氧、硫和氮连接基的新的吡嗪化合物
US11292801B2 (en) 2016-07-05 2022-04-05 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
WO2018011163A1 (en) * 2016-07-14 2018-01-18 F. Hoffmann-La Roche Ag 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine and 6,7-dihydro-4h-triazolo[1,5-a]pyrazine compounds for the treatment of infectious diseases
BR112019006110A2 (pt) 2016-09-28 2019-09-10 Blade Therapeutics Inc moduladores de calpaína e usos terapêuticos dos mesmos
TWI782056B (zh) * 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
US11247998B2 (en) 2017-07-27 2022-02-15 Jiangsu Hengrui Medicine Co., Ltd. Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine
AU2018326474B2 (en) 2017-08-28 2024-07-25 Enanta Pharmaceuticals, Inc. Hepatitis B antiviral agents
DK3681885T3 (da) 2017-09-15 2024-04-15 Forma Therapeutics Inc Tetrahydro-imidazo-quinolinsammensætninger som cbp/p300-inhibitorer
EP3704113B1 (en) 2017-11-01 2023-10-11 Bristol-Myers Squibb Company Bridged bicyclic compounds as farnesoid x receptor modulators
US11058678B2 (en) 2018-01-22 2021-07-13 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
WO2019191166A1 (en) * 2018-03-29 2019-10-03 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
CN111518016B (zh) * 2018-06-01 2022-02-25 厦门宝太生物科技股份有限公司 一种csf1r抑制剂中间体及其制备方法
AU2019295790B2 (en) 2018-06-29 2023-07-13 Forma Therapeutics, Inc. Inhibiting creb binding protein (CBP)
TW202024093A (zh) 2018-09-21 2020-07-01 美商安塔製藥公司 作為抗病毒劑之官能化雜環
EP3883570A4 (en) 2018-11-21 2022-07-13 Enanta Pharmaceuticals, Inc. FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS
JP7608166B2 (ja) 2019-01-11 2025-01-06 塩野義製薬株式会社 Ｍｇａｔ２阻害活性を有するジヒドロピラゾロピラジノン誘導体
CN111484497B (zh) * 2019-01-25 2021-07-02 江苏恒瑞医药股份有限公司 咪唑并[1,5-a]吡嗪类衍生物的可药用盐、晶型及其制备方法
WO2020151746A1 (zh) * 2019-01-25 2020-07-30 江苏恒瑞医药股份有限公司 1,2,3-三氮唑并[1,5-a]吡嗪类衍生物的晶型及其制备方法
CN111484498B (zh) * 2019-01-25 2021-05-14 江苏恒瑞医药股份有限公司 咪唑并[1,5-a]吡嗪类化合物的晶型及其制备方法
WO2020161257A1 (en) 2019-02-07 2020-08-13 Bayer Aktiengesellschaft 3-amino-2-[2-(acylamino)pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one as csnk1 inhibitors
EP3937940A4 (en) 2019-03-15 2022-12-21 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (creb)
WO2020247444A1 (en) 2019-06-03 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
US11472808B2 (en) 2019-06-04 2022-10-18 Enanta Pharmaceuticals, Inc. Substituted pyrrolo[1,2-c]pyrimidines as hepatitis B antiviral agents
WO2020247561A1 (en) 2019-06-04 2020-12-10 Enanta Pharmaceuticals, Inc, Hepatitis b antiviral agents
US11738019B2 (en) 2019-07-11 2023-08-29 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US11236108B2 (en) 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
WO2021188414A1 (en) 2020-03-16 2021-09-23 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
CN114057745A (zh) * 2020-07-29 2022-02-18 江苏恒瑞医药股份有限公司 一种三氮唑并[1,5-a]吡嗪制备方法及其应用
US20230339970A1 (en) * 2020-09-17 2023-10-26 Janssen Pharmaceutica Nv Casein kinase 1 delta modulators
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
TW202245772A (zh) * 2021-02-04 2022-12-01 大陸商江蘇恆瑞醫藥股份有限公司 一種衣殼蛋白抑制劑的醫藥組成物及其製備方法
WO2023147015A1 (en) * 2022-01-27 2023-08-03 The Broad Institute, Inc. Substituted heterocyclic csnk1 inhibitors
EP4538275A1 (en) * 2022-06-13 2025-04-16 Shionogi & Co., Ltd Crystal of dihydropyridinone derivative or solvate thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160915A0 (en) * 2001-09-19 2004-08-31 Aventis Pharma Sa Indolizines inhibiting kinase proteins
JP4691506B2 (ja) * 2003-12-11 2011-06-01 アベンティス・ファーマスーティカルズ・インコーポレイテツド カゼインキナーゼＩεの阻害剤としての置換１Ｈ−ピロロ［３，２−ｂ，３，２−ｃ，及び２，３−ｃ］ピリジン−２−カルボキシアミド及び関連類似物
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
CN101417999A (zh) 2007-10-25 2009-04-29 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用
EP2085398A1 (en) 2008-02-01 2009-08-05 Merz Pharma GmbH & Co. KGaA Pyrazolopyrimidines, a process for their preparation and their use as medicine
CN102223798A (zh) 2008-09-24 2011-10-19 巴斯夫欧洲公司 用于防治无脊椎动物害虫的吡唑化合物
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
TW201035102A (en) 2009-03-04 2010-10-01 Gruenethal Gmbh Sulfonylated tetrahydroazolopyrazines and their use as medicinal products
FR2960876B1 (fr) 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
CN102372716A (zh) 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
CA2826464C (en) 2011-03-02 2020-07-28 Lead Discovery Center Gmbh Pharmaceutically active disubstituted triazine derivatives
AR098414A1 (es) 2013-11-14 2016-05-26 Bristol Myers Squibb Co PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e

Also Published As

Publication number Publication date
US20160122358A1 (en) 2016-05-05
EP3068784A1 (en) 2016-09-21
ES2718218T3 (es) 2019-06-28
EP3068785B1 (en) 2019-06-26
JP6494624B2 (ja) 2019-04-03
CN105916856A (zh) 2016-08-31
US9598423B2 (en) 2017-03-21
US9273058B2 (en) 2016-03-01
CN105916856B (zh) 2018-09-25
JP2016537366A (ja) 2016-12-01
JP6494622B2 (ja) 2019-04-03
ES2744636T3 (es) 2020-02-25
CN105916855B (zh) 2019-03-15
AR098414A1 (es) 2016-05-26
WO2015073767A1 (en) 2015-05-21
TW201605859A (zh) 2016-02-16
CN105916855A (zh) 2016-08-31
JP2016537369A (ja) 2016-12-01
US20150133428A1 (en) 2015-05-14
EP3068784B1 (en) 2019-02-20
EP3068785A1 (en) 2016-09-21
US20160311824A1 (en) 2016-10-27
WO2015073763A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
UY35834A (es) Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon
CY1120635T1 (el) Βενζαμιδια αμινοετεροαρυλιου ως αναστολεις κινασης
MX372997B (es) Compuestos de aminopirimidina como inhibidores de jak.
PH12015500064A1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
MX2022002976A (es) Inhibidores selectivos de jak1.
CR20160035A (es) Inhibidores de bromodominios
MX374439B (es) Compuesto de piridona como inhibidor de c-met
NI201800042A (es) Nuevos derivados de pirrolo[2,3-d]pirimidina como inhibidores duales de dyrk1/clk1
EA202090291A3 (ru) Производные бипиразола в качестве ингибиторов jak
CR20150474A (es) Inhibidores de bromodominios tetracíclicos
EA201690848A1 (ru) Производные бициклического пиридила с конденсированными кольцами в качестве ингибиторов fgfr4
CR20160456A (es) Compuestos de heteroarilo o arilo bibíclicos fusionados
UY37205A (es) Inhibidores de bromodominios
CO6361936A2 (es) Imidazopiridazinacarbonitrilos utiles como inhibidores de quinasa
EA201491456A1 (ru) Соединения-ингибиторы raf
PH12014500883A1 (en) Uracil derivatives as axl and c-met kinase inhibitors
SV2017005405A (es) Compuestos y composiciones como inhibidores de quinasa raf
MX2016013265A (es) Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp.
MX2017012295A (es) Derivados formilados n-heterociclicos como inhibidores de fgfr4.
MX2016014939A (es) Derivados de carboxamida.
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
DK3083627T3 (da) [1,2,4]triazol[1,5-a]pyrimidinderivater som protozoiske proteasominhibitorer til behandling af parasitsygdomme, såsom leishmaniasis
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
EA201791099A1 (ru) Хинолин карбоксамиды для применения в лечении лейкоза
AR092772A1 (es) Derivado de 7-azaindol